Recombinant Human Pro-Urokinase vs. Alteplase Within 4.5 hours of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

By afschroeder • July 8, 2025

Hashmi TM, Shafiq A, Zia R, Ashraf H, Burhan M, Ahmed M, Mesmar A, Ahmed R, Fonarow GC. Recombinant Human Pro-Urokinase vs. Alteplase Within 4.5 hours of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Stroke Cerebrovasc Dis. 2025 Jul 5:108392. doi: 10.1016/j.jstrokecerebrovasdis.2025.108392. Epub ahead of print. PMID: 40623511.

Tags: alteplase, Cardiology/Epi, Publications, recombinant human pro-urokinase, stroke, thrombolytic therapy

Late-in-life treadmill-training mitigates gut microbiome imbalances and cardiovascular disease risk in mice

Cho JM, Park SK, Satheesh Babu AK, Mookherjee S, Hansen M, Petersen C, Zhong Y, Jalili T, Robeson MS, Whankade UD, Anandh Babu PV, Symons[...]

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

New strategies for valve replacement and interventional options in adults with congenital heart disease: new insights from Euro-ACHD 2025

Butera G, Chessa M, Gaio G, Kempny A, Uebing A, Michielon G, Aboulhosn J, Giamberti A, Hoschtitzky A, d'Udekem Y. New strategies for valve replacement[...]